trade name orthoclone marketed janssencilag immunosuppressant drug given reduce acute rejection patients organ monoclonal antibody targeted membrane protein surface cells first monoclonal antibody approved clinical use approved us food drug administration fda making first monoclonal antibody approved anywhere drug humans european communities first drug approved directive precursor european medicines agency emea centralised approval system european union process included assessment committee proprietary medicinal products cpmp chmp subsequent approval national health agencies germany example paul ehrlich institute frankfurt however manufacturer voluntarily united states market due numerous sideeffects bettertolerated alternatives declining approved therapy acute glucocorticoidresistant rejection allogeneic renal heart liver unlike monoclonal antibodies basiliximab daclizumab approved prophylaxis transplant rejection although review found safe also investigated use treating tcell acute lymphoblastic cells recognise antigens primarily via cell receptor one proteins make tcr tcr transduces signal cell proliferate attack murine mouse monoclonal antibody created using hybridoma binds cell specifically epsilon chain surface circulating cells initially leading subsequently inducing clearance tcr complex cell surface apoptosis protects transplant administered transplant induction drug administered daily thereafter newer monoclonal antibodies development mechanism action include otelixizumab also known teplizumab also known visilizumab tentative trade name nuvion investigated treatment conditions like crohns disease ulcerative colitis type diabetes development teplizumab uncertain due oneyear data recent phase iii trial especially first infusion binding activate cells release cytokines like tumor necrosis factor interferon gamma cytokine release syndrome crs includes side effects like skin reactions fatigue fever chills myalgia headaches nausea could lead lifethreatening conditions like apnoea cardiac arrest flash pulmonary minimize risk crs offset minor side effects patient experience glucocorticoids methylprednisolone acetaminophen diphenhydramine given adverse effects include leucopenia well increased risk severe infections malignancies typical immunosuppressive therapies neurological side effects like aseptic meningitis encephalopathy observed possibly also caused cell repeated application result tachyphylaxis reduced effectiveness due formation antimouse antibodies patient accelerates elimination drug also lead anaphylactic reaction mouse may difficult distinguish crs except special circumstances drug contraindicated patients allergy mouse proteins well patients uncompensated heart failure uncontrolled arterial hypertension epilepsy used pregnancy developed nomenclature monoclonal antibodies took effect consequently name follow convention instead contraction murine monoclonal antibody targeting